Clinical efficacy of recombinant human brain natriuretic peptide on heart failure

XU Yong-shun; Zhang Xiao dong; Zhou Qiang; Bian Wei

doi:10.3969/j.1674-4055.2014.03.23

Abstract：Objective To observe the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) on acute heart failure or acute attacked chronic heart failure (CHF). Methods The patients (n=65) were randomly divided into observation group (n=33) and control group (n=32). On the base of routine treatment for heart failure (diuretics, ACE inhibitor,β-receptor blockers, etc.), observation group was given rhBNP [first dose=1.5μg/kg, maintaining dose=0.0075μg/(kg.min)], and control group was given nitroglycerin (first dose=5-10μg/min, increased 5μg-10μg according blood pressure until average dose=20μg/min) by intravenous pumping for 48 h. The clinical efficacy and changes of LVEF, NT-proBNP, pulmonary artery pressure (PAP), heart rate (HR), respiratory rate (RR), length of hospital stay, mortality, 6-minute walk distance (6MWD) after 3 m and rehospitalizing rate were observed in 2 groups. Results The total effective rate was 96.9%in observation group and 68.8%in control group (P<0.05). Before treatment the changes of LVEF, NT-proBNP, HR, RR and PAP had no statistical difference between 2 groups (P>0.05). After treatment for 48 h, LVEF increased, and NT-proBNP, HR, RR and PAP decreased in observation group (P<0.05), while in control group, all above indexes had no statistical difference before and after treatment (P>0.05). The length of hospital stay was shortened significantly, mortality decreased, 6MWD after 3 m incrased and rehospitalizing rate decreased in observation group compared with control group (P<0.05). Conclusion The early administration of rhBNP can relieve symptoms and improve prognosis in the patients with acute heart failure or acute attacked CHF, and its curative effect is better than that of nitroglycerin.